We all know someone waiting on a medical breakthrough. It could be a parent battling a chronic illness, a colleague pushing through long workdays while managing treatment, or a child whose options have not changed in decades. And while the human cost is clear, there is also a business cost that is just as real. Slow drug development pulls people out of the workforce, raises insurance premiums, and forces companies to absorb productivity losses that can cause a ripple across the economy.
The delays are often caused by bottlenecks from regulation or clinical trials. But most importantly and often overlooked is the speed at which scientists can understand what a drug does at the molecular level. When that process is slow or imprecise, companies burn capital, investors lose confidence, and promising ideas can die. This is where Dr. Marek Polák is hoping to make a difference.
Dr. Polák develops advanced mass spectrometry tools that allow scientists and companies to analyze biomolecules with extraordinary detail. While his work lives deep inside the lab, its impact shows up in balance sheets. “If you can answer those questions earlier and more confidently, you kill bad projects sooner and double down on promising ones faster,” he says. That clarity is a direct commercial advantage in an industry where timelines determine survival.
For startups, this matters more than almost anything else. Early-stage biotech companies often spend their first two years validating whether an idea is even viable. Subtle molecular flaws can sink a program, but they are rarely visible until late-stage testing. With high-resolution analytics, those flaws surface earlier. The result is fewer wasted years and more efficient use of venture capital. In a sector where a single failure can end a company, better instrumentation can be a pathway to success.
There are also national implications. Countries that control the most advanced analytical tools set the standards for drug quality, biologics approval, and emerging therapies. This shapes global markets. “The countries that control the best analytical capabilities tend to set the bar for drug quality, biosimilar approval, and advanced therapies,” Dr. Polák explains. If the U.S. wants to remain the leader in biotech, it must lead in measurement, not just discovery.
That leadership also affects supply chains. When pharmaceutical quality testing depends on foreign validation, companies expose themselves to geopolitical risk and delays. Advanced domestic analytical capacity strengthens resilience by allowing drugs, biologics, and critical materials to be fully characterized in the United States. That reduces dependency and improves speed to market, both of which matter to investors and the companies they fund.
Dr. Polák’s work also extends into sectors most people do not associate with biotech. High-resolution mass spectrometry is used in food safety to detect contaminants, in agriculture to monitor pesticides, in energy to analyze complex petroleum mixtures, and in advanced materials to track degradation in batteries. Each application reduces waste, increases reliability, and supports job creation in high-skill technical roles.
Diagnostics may be where the return on investment is most immediate. The U.S. healthcare system still rewards late-stage intervention rather than early detection, even though chronic disease drives long-term costs. Molecular diagnostics can detect subtle changes long before symptoms appear, but scaling that capability requires standardization and automation. “We need standardized workflows so that a readout in Bay Area means the same thing as a readout in Florida,” Dr. Polák says. That consistency is what transforms a research breakthrough into national health and wellness infrastructure.
His perspective is informed by experience in both European and American research systems. Europe excels at foundational science but often struggles with translation. The U.S., by contrast, is designed to turn ideas into products quickly. Universities, venture capital, and industry collaborate in ways that accelerate commercialization. But that system only works if the data guiding early decisions is accurate. Precision tools strengthen the entire innovation engine.
There is a misconception that instrumentation work is slow and niche, yet the reality is that it is leverage. When performance improves, that improvement propagates across hundreds of downstream products and industries. Dr. Polák shared, “When we improve the performance of an instrument providing a readout of our sample, that improvement doesn’t just help one experiment in my lab, it can propagate into many industries and hundreds of downstream products.”
America’s biotech future will not be decided by a single breakthrough drug. It will be decided by how quickly and confidently companies can test ideas, scale innovation, and move from discovery to impact. By strengthening the tools that power that process, Dr. Polák is helping ensure the U.S. stays competitive, productive, and healthy.
